The multi-target small molecule anticancer drug nintedanib shows promising effectiveness in stopping the growth of human malignant pleural mesothelioma, a fatal thoracic tumor, in preclinical models, according to a new study ...
May 16, 2018
0
1
Early specialist palliative care for patients that were recently diagnosed with malignant pleural mesothelioma (MPM) does not impact quality of life (QOL) measures, according to research presented by Prof. Fraser Brims of ...
Oct 16, 2017
0
0
Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School ...
Mar 20, 2017
0
0
Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malignant pleural mesothelioma. For the first time in the world, they were able to show ...
Oct 24, 2016
0
4
The Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke's Medical Center has begun enrolling patients in a clinical research study looking at an investigational drug in patients with malignant pleural ...
Sep 15, 2016
0
2
Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life.
Jun 9, 2016
0
2
Mesothelioma is a rare but deadly form of cancer: the five-year survival rate for patients diagnosed with the disease is between five and ten percent. Although aggressive surgery can help some patients with early-stage mesothelioma, ...
Feb 29, 2016
0
336
A new study suggests that significant improvements could be made in the scoring system physicians use to estimate the stage (severity) of mesothelioma, an aggressive and deadly cancer.
Feb 2, 2016
0
1
A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma (MPM), according to an article in the September 2015 issue ...
Sep 8, 2015
0
12
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the ...
Apr 20, 2015
0
7
